Who pays for recommended drugs? Drug insurance companies do and they will block the use of new drugs as they usually do with Protocols and High Co-Pays that no patient wants to pay. Especially with so many other generic products available with low Co-Pays and tiny needle insulin Pens that patients love. Also, some doc's have been recommending early start insulin for the T2's for many years...its not a new theory. Some of you think its "new" thinking", its not. I heard that talk over 15 years ago. So having an inhaled insulin will not see much of a bump on early insulin use. Sorry guys, this drug will be used in only a few "special cases " ( recurrent MRSA skin infections, severe bleeding disorders, poor vision, maybe documented Needle Phobia, etc ) . Maybe 1% of the Diabetic T1/T2's. The MNKD story is in the technology for other drugs...Not inhaled insulin...by the way - this has already failed the stockholders with such a poor showing-very low price targets etc, . Now if you want, take a little more Kool-Aid.
" Afrezza could be used as a first-line insulin for almost 8% of type 2 patients "- 8% first line NO WAY...yeah and your seat cushion could be a flotation device....Dude Afrezza will be lucky to be used for 1% of the Diabetics t1/t2.
Wow, this stock is a JOKE.
I hate it. It doesn't exactly roll off the tongue does it. BUT it is very unique sounding name. So
for that reason it may be a great choice.
Sorry for your pain, but another antibiotic just won't double your stock from the current OVER PRICED $10 to $20. NO WAY, NO HOW, NEVER.
CEMP ....really. They have that one P3 trial going, its an antibiotic ( I believe in the same family as Zithromycin, correct me if I am wrong) ...unless its an incrediable "Gorilla-cillin " it will be one of many antibiotics and won't make " big headlines" the way anti-cancer drugs do. Today with Big Pharm...one great antibiotic gets replaced in 1-2 years with another BETTER antibiotics, Zithromax may be an exception. Not to mention CAMP's drug is for Out-patient moderate pneumonia. Heck doctors still Rx Zithromycin - cheap, long acting. For mild mod MRSA- they can still use Septra sometimes. Right now depending on where the P3 trial is you are looking at 8-12 months minimum for a NDA-MAYBE. It would make a nice speculative investment under $5. Now its $10, I wouldn't touch it. Why? There are just too many antibiotic P2 & P3 trials for antibiotics. Tons of competition. Imagine PIMA was one of 20-30 PDP drugs...get it now.
High Beta (ACAD 2.75) stocks esp biotechs, always attract shorts. Most longs here held this when it retraced down to $15+, we didn't sell then. So now the strong hands gripping tighter as the NDA approaches. Shorts starting to figure it out.
What a lot of people don't realize is the money that any Pharmacy saves by having low inventory (partial fills of brand name drugs), using generic drugs, etc. Save's YOU money. That is why your Health Insurance contracted with WAG, because they offered lower cost drugs. Otherwise, your health insurance would have to go to a higher cost pharmacy and believe me they will eventually pass the higher cost on TO YOU. So if you want that higher cost "Beverly Hills" pharmacy, then you will pay for it via Higher price health care - monthly premiums and co-pays.
Walgreens...I shop there. Their store is well run and has a good selection of products. They have the best selection of batteries I have ever seen and I did an evaluation of this a few months back. Better than Home Depot. As far as the pharmacy goes, I use it once 'n a while. I have have had no problems. Some of the issues mentioned by swamp are typical of pharmacy trying to keep low inventories, following insurance companies protocols and high prices of brand name drugs. So get use to it, these are bottom line issues that help WAG rake in the cash. Check their stats, they make good Rev's although less than CVS , but they have more cash and less debt that CVS. So fairly well run, the recent "glich" is probably a short term problem that can be fixed. If I was thinking buying opportunity I would watch the TA Indicators & Candlestick chart CLOSELY for signs of reverse, then try to buy on a RED DAY. Let the rats abandon the ship first. Then I would only buy about 25% of my total investment. Watch the EMA 5/20 etc. good luck
As we approach the fall its going to run. But I would still take caution with buying on UP days. I like to buy on Red days. Still plenty of time to add on to your core holdings. Looks like good support at $ 22.13. Today, buying came in , perhaps some shorts starting to figure out its getting close to the end of the line for them in this range. I suppose some dimwits are still hoping for $ 15-19. Ah.....don't hold your breath.
Type Value Conf.
resist. 28.78 2
resist. 25.30 2
resist. 23.70 4
resist. 23.21 3
supp 22.13 12
supp 21.05 5
supp 20.08 10
supp 19.27 4
supp 17.88 4
Ind. short Inter Long
EMA VBu VBu VBu
MACD VBu Bu N
Fibs VBu Bu Be
Highs VBe VBe VBe
Lows VBu Bu Bu
Trends Bu N N
Read moreRecent CandleStick Analysis
Aug-21-2014 Bearish Engulfing
Aug-19-2014 Bullish Harami
Acadia Pharmaceuticals Incorporated
Daily Short Sale Volume
Short Interest (Shares Short)
Days To Cover (Short Interest Ratio)
Short Percent of Float
Short Interest - Prior
Short % Increase / Decrease
Its now riskier to short than to buy & hold.
Afrezza....will only get about 1% of the diabetic market and sales could be VERY DISAPPOINTING. But good company fundamentals could keep this stock from a future huge DUMP when the first Q sales are announced.
They must increase SHAREHOLDER VALUE- they don't seem to remember that concept.
Must not issue more shares for at least 1 year
Must pay off some debt
Continue to stay on all 4 cylinders with their R&D
Avoid excessive bonus and compensation
Top-down Critical review & consolidation of all major costs & spending
Reach out for other partners to develop more revenue streams
Critical review and monitoring of all current revenue streams
Most likely the company is already doing many of these steps and more, but I think they need to go back to the drawing board and take another look at their internal processes. They have succeeded and failed. They need to recognize that despite their great success in bringing Afrezza to approval they have also failed to bring value to the shareholders. Why? The company fundamental have come back to haunt them. As long as they place their "success " above basic company fundamental shareholder value will never reach the full potential it should. If the CEO can't see that, he should be voted out.
Basically, re-visit Good Company Fundamentals.
As a side issue, a mediocre performance has no place here - I would strongly consider firing that moron that was not prepared and mentioned he had a "tired brain" during the last news conference. For a top executive in a major company to be unprepared - not having the simple number of OS is just pitiful. I would not want this lacky on my team. Then he makes a lame excuse of having a "tired brain " to an open news conference
web cast. Just unforgivable.
Afrezza is the validation of that technology. It is not a bock buster. But will get the ball rolling for new Revenue stream and is only the first of a line of inhaled products. This stock is no longer a speculative stock. Its a long term investment. So you own it- better get use to the term "dead money" at least till the sales numbers come in. It succeeded where PFE failed (so far). What is the next drug to get close to a NDA?
This is about the future now, how about space suit inhaled meds - so your out on a long space walk and you get a severe muscle cramp...Well you can't reach in you pocket and take a pill, you can't give your self a shot....just push a button and inhaled anti cramp med shoots into your mouth. I might be ahead of my time?